Lantheus Seeks FDA Approval of PyL Prostate Cancer Imaging Agent
News
Lantheus Holdings has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval of PyL, an investigational imaging agent used to locate prostate cancer lesions. The new ... Read more